| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.34▼ | 2.33▼ | 2.36▼ | 2.56▼ | 3.13▼ |
| MA10 | 2.33▼ | 2.37▼ | 2.40▼ | 2.62▼ | 4.01▼ |
| MA20 | 2.36▼ | 2.39▼ | 2.46▼ | 3.09▼ | 5.33▼ |
| MA50 | 2.38▼ | 2.51▼ | 2.53▼ | 4.22▼ | 6.93▼ |
| MA100 | 2.46▼ | 2.59▼ | 2.81▼ | 5.43▼ | N/A |
| MA200 | 2.50▼ | 3.01▼ | 3.50▼ | 6.40▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | -0.005▼ | -0.009▼ | 0.008▲ | -0.323▼ |
| RSI | 41.690▼ | 38.086▼ | 35.062▼ | 25.328▼ | 23.151▼ |
| STOCH | 70.343 | 13.681▼ | 18.996▼ | 26.317 | 3.764▼ |
| WILL %R | -52.941 | -88.889▼ | -88.889▼ | -94.613▼ | -98.527▼ |
| CCI | -46.624 | -98.990 | -98.647 | -98.322 | -129.402▼ |
|
Monday, March 09, 2026 07:17 AM
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancersMechanisms of action support enhanced activity of GSK-3β plus RAS ...
|
|
Wednesday, March 04, 2026 09:00 AM
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
|
|
Monday, February 23, 2026 11:45 PM
Detailed price information for Actuate Therapeutics Inc (ACTU-Q) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 20/03/26 | 2.52 | 2.70 | 2.27 | 2.35 | 110,474 |
| 19/03/26 | 2.55 | 2.60 | 2.31 | 2.50 | 116,446 |
| 18/03/26 | 2.70 | 2.7136 | 2.50 | 2.52 | 63,936 |
| 17/03/26 | 2.70 | 2.80 | 2.605 | 2.77 | 80,309 |
| 16/03/26 | 2.55 | 2.7499 | 2.48 | 2.68 | 116,099 |
| 13/03/26 | 2.55 | 2.6599 | 2.42 | 2.56 | 120,715 |
| 12/03/26 | 2.45 | 2.59 | 2.33 | 2.55 | 134,325 |
| 11/03/26 | 2.89 | 3.0489 | 2.5001 | 2.52 | 97,617 |
| 10/03/26 | 3.0207 | 3.0301 | 2.7401 | 2.84 | 49,130 |
| 09/03/26 | 2.85 | 3.1088 | 2.64 | 2.945 | 91,339 |
|
|
||||
|
|
||||
|
|